Remimazolam and Endovascular Procedures of Cerebrovascular Diseases
Status:
Not yet recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
Remimazolam, a novel ultra-short acting benzodiazepine that combined the advantages of
midazolam and remifentanil, has been developed for procedural sedation, induction and
maintenance of general anesthesia, and sedation in the ICU. Previous studies have suggested
that efficacy and safety of remimazolam are not inferior to propofol or midazolam in patients
undergoing colonoscopy,bronchoscopy and some other treatments. However, the efficacy and
potential adverse effects of remimazolam on patients undergoing endovascular procedures of
cerebrovascular disorders is still unclear. In this study, we tend to conduct a
single-center, randomized, single-blind ,non-inferiority trial to compare the efficacy and
safety of remimazolam and propofol in endovascular procedures of cerebrovascular disorders.